- 56. The immunologically isolated stromal cells of claim 37, wherein said beneficial protein is selected from the group consisting of a type II procollagen, a type II collagen, a cystic fibrosis protein, a human growth hormone, an obesity factor, and a human Factor VIII.
- 57. The immunologically isolated stromal cells of claim 37, wherein said gene construct is transfected into said stromal cells using a method selected from the group consisting of calcium phosphate precipitation transfection, DEAE dextran transfection, electroporation, microinjection, liposome-mediated transfer, chemical-mediated transfer, ligand-mediated transfer, and recombinant viral vector transfer.
- 58. The immunologically isolated stromal cells of claim 37, wherein said cells are matched donor stromal cells.
- 59. The immunologically isolated stromal cells of claim 37, wherein said regulatory elements comprise at least one of a promoter, a polyadenylation signal, an initiation codon, and a stop codon.
- 60. The immunologically isolated stromal cells of claim 59, wherein said promoter is selected from the group consisting of a cytomegalovirus promoter, an SV40 promoter, a retroviral promoter, a human procollagen I promoter, a human procollagen III promoter, a COL1A1 promoter, and a COL2A1 promoter.
- 61. The immunologically isolated stromal cells of claim 59, wherein said polyadenylation signal is selected from the group consisting of a human collagen I polyadenylation signal, a human collagen II polyadenylation signal, and an SV40 polyadenylation signal.
- 62. The immunologically isolated stromal cells of claim 37, where said gene construct also comprises a second gene.
- 63. The immunologically isolated stromal cells of claim 62, wherein said second gene encodes a detectable marker.
- 64. The immunologically isolated stromal cells of claim 63, wherein said detectable marker is an antibiotic resistance gene.